IL‐38: A novel cytokine in systemic lupus erythematosus pathogenesis

• Published in: Journal of cellular and molecular medicine 2020-11, Vol.24 (21), p.12379-12389
• Main Authors: Xu, Wang‐Dong, Su, Lin‐Chong, Liu, Xiao‐Yan, Wang, Jia‐Min, Yuan, Zhi‐Chao, Qin, Zhen, Zhou, Xi‐Ping, Huang, An‐Fang
• Format: Article
• Language: English
• Subjects: Age; Arthritis; autoimmunity; Cell culture; Cytokines; Females; Gene expression; Hematuria; IL‐38; Inflammation; Kidneys; Laboratories; Leukocytes (mononuclear); Lupus; Males; Original; Pathogenesis; Patients; Peripheral blood mononuclear cells; Plasma; Plasma levels; Pristane; Proteinuria; Skin; Systemic lupus erythematosus; Tumor necrosis factor
• ISSN: 1582-1838; 1582-4934
• DOI: 10.1111/jcmm.15737

IL‐38 is a newly identified cytokine that belongs to the IL‐1 family. In our previous study, we found elevated plasma levels of IL‐38 in patients with systemic lupus erythematosus (SLE). However, the clear relationship of IL‐38 expression in plasma, peripheral blood mononuclear cells (PBMCs) and clinical and laboratory features needs elucidation. Additionally, we evaluated the possible role of IL‐38 in regulating production of inflammatory cytokines in PBMCs in vitro. A pristane‐induced murine lupus model was used to further demonstrate the effects of IL‐38 on cytokines in vivo and discuss the significance of IL‐38 in lupus development. The results showed that mRNA expression of IL‐38 in PBMCs of patients with SLE was elevated compared with volunteers, and expression of IL‐38 in both plasma and PBMCs was strongly related to clinical features, such as haematuria and proteinuria, and correlated with a SLEDAI score. Plasma levels of TNF‐α, IL‐1β, IL‐6 and IL‐23 were elevated in patients with SLE and were related to plasma levels of IL‐38. In vitro, PBMCs of patients with SLE stimulated with IL‐38 showed a decreased expression of the four inflammatory cytokines compared with PBMCs of patients without treatment. Interestingly, IL‐38 administration in lupus mice significantly reduced the development of lupus, such as reduced proteinuria, improved histological examinations of the kidneys and down‐regulated inflammatory cytokines. In conclusion, IL‐38 may suppress synthesis of pro‐inflammatory cytokines and therefore regulate lupus pathogenesis.